PressAugust 11, 2022 PsyBio Therapeutics Strengthens IP Portfolio through Filing of Data to Support Previously Submitted Provisional Biosynthetic Production Patent Application
PressAugust 11, 2022 Lobe Sciences Enters into an Exclusive Agreement With iNGENu to Conduct Clinical Trials in Australia
PressAugust 10, 2022 Optimi Health Unveils Canada’s First Natural Therapeutic Psilocybin Product For Approved Patients
PressAugust 10, 2022 Psilera’s New Compounds Show Potential for Significant Treatment Improvement in Depression and Neurodegenerative Disorders
BlogAugust 10, 2022 Jordan Youkilis Provides Capital To Next-Generation Industries – Psychedelic Investors #2
PressAugust 9, 2022 PsyBio Therapeutics Announces Expansion of Patent Portfolio with Additional Global Patent Applications
PressAugust 9, 2022 Revitalist Announces Release of Three Proprietary Service Lines Advancing Their Comprehensive Footprint in the Mental Health and Psychedelic Wellness Space
PressAugust 9, 2022 Optimi Health To Launch Therapeutic Psilocybin Product In Partnership With Patient Advocate Thomas Hartle
PressAugust 9, 2022 Cybin Inc. Reports First Quarter Financial Results and Recent Business Highlights
PressAugust 9, 2022 Irwin Naturals Completes Georgia Acquisition, Adds Two Ketamine Clinics to National Chain
PressAugust 9, 2022 Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder
